News for Aquestive Therapeutics, Inc. (AQST)

**media[545447]**

**media[538616]**

Data show Anaphylm maintains consistent stability and potency under extreme temperature and real-world conditions, including heat, freezing, and water submersio

**media[531569]**

On track to submit Anaphylmâ„¢ (epinephrine) Sublingual Film NDA in Q1 2025Actively recruiting subjects in the Anaphylm pediatric clinical trialSuccessfully com

Aquestive Therapeutics' Anaphylm is nearing FDA approval, potentially disrupting the U.S. anaphylaxis market dominated by EpiPen. See why AQST stock is a Buy.

Aquestive Therapeutics (AQST) has received FDA Orphan Drug Exclusivity for its drug Libervant Buccal Film in the treatment of seizure clusters in children aged two to five years.

Aquestive Therapeutics confirms FDA nod for Anaphylm trial

Reaffirms New Drug Application (NDA) first quarter 2025 submission guidanceConfirms no additional adult clinical trials are necessary prior to NDA submission Co

Aquestive therapeutics COO Jung Cassie sells $214 in stock

Following underperformance in Q2 2024, the Franklin Biotechnology Discovery Fund returned to strength in Q3 2024. Click here to read the full commentary.

November has been an eventful month so far for the market as the Fed cut rates by a quarter percentage and president-elect, Donald Trump won the election for the second time.

Aquestive Therapeutics announces board changes

Total Revenue: $13.5 million in Q3 2024, a 4% increase from $13 million in Q3 2023.Manufacture and Supply Revenue: Decreased to $10.7 million in Q3 2024 from $

ARS Pharmaceuticals' neffy, a needle-free nasal spray for allergies, receives FDA approval, driving stock price up 120%. Read more on SPRY stock here.

Stocks Analysis by Joel Latham covering: Eli Lilly and Company, Pfizer Inc, Redhill Biopharma Ltd, Corbus Pharmaceuticals Holding. Read Joel Latham's latest article on Investing.com

The Global Oral Transmucosal Drugs Market Size was Valued at USD 33.2 Billion in 2023 and the Worldwide Oral Transmucosal Drugs Market Size is Expected to...

U.S. stocks traded higher toward the end of trading, after the Federal Reserve left rates unchanged. The Dow traded up 0.91% to 39,467.76 while the NASDAQ rose 1.08% to 16,341.42. The S&P 500 also rose, gaining, 0.78% to 5,218.70.

Shares of Lifecore Biomedical, Inc. (NASDAQ: LFCR) fell sharply during Wednesday’s session after the company announced it concluded its strategic evaluation process, announced management succession and board changes. Lifecore Biomedical shares dipped 31.7% to $4.91 on Wednesday.